| Title |
Cancer therapy and cardiovascular risk: focus on bevacizumab
|
|---|---|
| Published in |
Cancer Management and Research, June 2015
|
| DOI | 10.2147/cmar.s77400 |
| Pubmed ID | |
| Authors |
Panagiota Economopoulou, Athanasios Kotsakis, Ioannis Kapiris, Nikolaos Kentepozidis |
| Abstract |
Recognition and management of treatment-related cardiovascular toxicity, defined as either an acute cardiac event or a chronic condition, has been tightly integrated into routine cancer care and has become an important component in treatment selection. Several chemotherapeutic agents, such as anthracyclines, are traditionally characterized as cardiotoxic, but cardiovascular adverse events are also associated with commonly used molecular targeted therapies. In the past decade, bevacizumab, a monoclonal humanized antibody against vascular endothelial growth factor, has been introduced in the treatment of a variety of metastatic malignancies. Despite its efficacy, bevacizumab has been associated with significant risk of cardiovascular complications, such as hypertension, cardiac ischemia, and congestive heart failure. This review will focus on the cardiovascular toxicity of bevacizumab, providing the latest evidence on the incidence, clinical spectrum, risk factors, and responsible mechanisms. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | 33% |
| Canada | 1 | 33% |
| Unknown | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 2 | 67% |
| Members of the public | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 78 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| France | 1 | 1% |
| Unknown | 77 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 11 | 14% |
| Student > Bachelor | 9 | 12% |
| Student > Postgraduate | 8 | 10% |
| Student > Master | 6 | 8% |
| Student > Doctoral Student | 5 | 6% |
| Other | 19 | 24% |
| Unknown | 20 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 28 | 36% |
| Biochemistry, Genetics and Molecular Biology | 6 | 8% |
| Unspecified | 4 | 5% |
| Agricultural and Biological Sciences | 4 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 5% |
| Other | 5 | 6% |
| Unknown | 27 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 November 2021.
All research outputs
#16,868,837
of 25,584,565 outputs
Outputs from Cancer Management and Research
#690
of 2,067 outputs
Outputs of similar age
#159,689
of 281,752 outputs
Outputs of similar age from Cancer Management and Research
#6
of 11 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one is in the 32nd percentile – i.e., 32% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,067 research outputs from this source. They receive a mean Attention Score of 3.5. This one has gotten more attention than average, scoring higher than 62% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 281,752 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 54% of its contemporaries.